fluorodeoxyglucose f18 has been researched along with Pseudomyxoma Peritonei in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gohda, Y; Hotta, M; Igari, T; Minamimoto, R; Yano, H | 1 |
| Bakrin, N; Dubreuil, J; Giammarile, F; Glehen, O; Isaac, S; Passot, G; Rousset, P; Skanjeti, A | 1 |
| Colletti, PM; Dubreuil, J; Giammarile, F; Glehen, O; Rousset, P; Rubello, D; Skanjeti, A | 1 |
| Cotte, E; Giammarile, F; Gilly, FN; Glehen, O; Isaac, S; Mohamed, F; Passot, G; Pellet, O; Tychyj, C | 1 |
| Cromer, M; Levine, EA; Rohani, P; Russell, GB; Scotti, SD; Shen, P; Stewart, JH | 1 |
1 review(s) available for fluorodeoxyglucose f18 and Pseudomyxoma Peritonei
| Article | Year |
|---|---|
18F-FDG-PET/CT of peritoneal tumors: a pictorial essay.
Topics: Carcinoma; Desmoplastic Small Round Cell Tumor; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Mesothelioma; Ovarian Neoplasms; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Pseudomyxoma Peritonei; Radiopharmaceuticals; Sarcoma; Stomach Neoplasms | 2017 |
1 trial(s) available for fluorodeoxyglucose f18 and Pseudomyxoma Peritonei
| Article | Year |
|---|---|
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.
Topics: Adult; Aged; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Preoperative Period; Pseudomyxoma Peritonei; Recurrence | 2016 |
3 other study(ies) available for fluorodeoxyglucose f18 and Pseudomyxoma Peritonei
| Article | Year |
|---|---|
Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Topics: Female; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Neoplasm Grading; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Pseudomyxoma Peritonei; Radiopharmaceuticals; Survival Rate | 2019 |
Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Laparotomy; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Pseudomyxoma Peritonei; Radiopharmaceuticals | 2010 |
Use of FDG-PET imaging for patients with disseminated cancer of the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Appendiceal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Peritoneal Neoplasms; Positron-Emission Tomography; Pseudomyxoma Peritonei; Radiopharmaceuticals; Survival Analysis | 2010 |